SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ranbaxy Laboratories has reported results for third ended September 30, 2012.

The company has reported net profit of Rs 552.19 crore for the quarter as compared to a net loss of Rs 439.20 crore for the same quarter in the previous year. Total income of the company has increased by 5.60% at Rs 1527.36 crore for quarter under review as compared to Rs 1446.41 crore for the quarter ended September 30, 2011.

Ranbaxy Laboratories is India's largest pharmaceutical company. The company has global presence in 49 countries and is ranked amongst top ten global generics companies. Ranbaxy has world-class manufacturing facilities in 11 countries namely Brazil, China, Ireland, India, Japan, Malaysia, Nigeria, Romania, South Africa, USA and Vietnam.

Peers
Company Name CMP
Sun Pharma Inds. 1874.15
Dr. Reddys Lab 1284.45
Cipla 1336.25
Zydus Lifesciences 938.15
Lupin 2251.70
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×